Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer. Reply
N Engl J Med
.
2025 Feb 20;392(8):830-831.
doi: 10.1056/NEJMc2416654.
Authors
Aditya Bardia
1
,
Maria Schwaederle
2
,
Giuseppe Curigliano
3
Affiliations
1
University of California, Los Angeles, Los Angeles.
2
AstraZeneca, Gaithersburg, MD.
3
University of Milan, Milan.
PMID:
39970414
DOI:
10.1056/NEJMc2416654
No abstract available
Publication types
Letter
Comment